Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1679
    +0.0022 (+0.19%)
     

  • GBP/USD

    1.2491
    -0.0020 (-0.16%)
     

  • Bitcoin GBP

    51,225.37
    -577.71 (-1.12%)
     

  • CMC Crypto 200

    1,334.03
    -62.51 (-4.32%)
     

  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     

  • DOW

    38,239.66
    +153.86 (+0.40%)
     

  • CRUDE OIL

    83.66
    +0.09 (+0.11%)
     

  • GOLD FUTURES

    2,349.60
    +7.10 (+0.30%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Bausch (BHC) Reports Q1 Earnings: What Key Metrics Have to Say

Zacks Equity Research
·2-min read

Bausch Health (BHC) reported $1.94 billion in revenue for the quarter ended March 2023, representing a year-over-year increase of 1.4%. EPS of $0.52 for the same period compares to $0.72 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $1.95 billion, representing a surprise of -0.32%. The company delivered an EPS surprise of -30.67%, with the consensus EPS estimate being $0.75.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

ADVERTISEMENT

Here is how Bausch performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Revenues- Total Bausch + Lomb revenues: $931 million versus the three-analyst average estimate of $893.90 million. The reported number represents a year-over-year change of +4.7%.

  • Revenues- Total Diversified Products: $197 million versus the three-analyst average estimate of $232.58 million.

  • Revenues- Salix: $496 million versus the three-analyst average estimate of $489.43 million. The reported number represents a year-over-year change of +6.9%.

  • Revenues- Solta Medical: $73 million compared to the $80.55 million average estimate based on three analysts.

  • Revenues- International: $247 million versus the three-analyst average estimate of $253.72 million. The reported number represents a year-over-year change of +1.2%.

View all Key Company Metrics for Bausch here>>>

Shares of Bausch have returned -0.3% over the past month versus the Zacks S&P 500 composite's -0.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Bausch Health Cos Inc. (BHC) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research